Oligonucleotide (Antisense oligonucleotide) · Gene silencing: GFAP · developed by Ionis Pharms
Zilganersen is an antisense oligonucleotide administered by intrathecal injection. It is being studied in Alexander Disease, a rare neurological disorder.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04849741 | Phase 3 | Alexander Disease | Active not recruiting | IONS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alexander Disease
Updated Oct 3, 2026. Something wrong or missing? Report it on the IONS page.
See IONS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IONS catalysts and pipeline →